I have seen this study before, there are significant issues with it as far as I am concerned,
Swapping to lower doses or less frequent doses when weight loss has ceased , which takes about a year or a bit more, is different to doing it when weight loss is still ongoing. Their definition of weight loss stalling is less than 5% change in 3 months, which is equivalent to less than 20% over a year, which is very rapid weight loss not stalling. I think this error invalidates a lot of what the study is trying to prove. It may be that weight loss had actually ceased, but there is no way of knowing due to the very poorly defined stall point. Weight loss that was still ongoing at a given dose being maintained at that dose being given less often is what I would expect to happen. Weight loss that had truly ceased being maintained by less frequent dosing is not what I would expect and would be showing something different to all the other research. All the studies that had long tern follow up on ongoing therapy showed weight loss being maintained at the dose used to lose the weight in the first place. Given that this study is trying to show something that disagrees with many other large studies all showing the same thing, it needs to show extra high quality evidence to support it's argument. A study with few participants with not very well designed definitions, does not prove much at all, compared with multiple very large scale studies done to demonstrate the drugs effectiveness at maintaining weight loss had many hundreds of participants , and results were consistent for all the different GLP drugs, weight loss is maintained at the dose used to lose the weight. I do not think this study disproves that.